“We are at a new and powerful moment in the fight against cancer. By shining a light on the genomic alterations responsible for cancer’s growth, we can now design innovative treatments specifically directed at the most relevant molecular targets and identify those patients who are most likely to benefit. Finally, cancer treatment has the potential to function the way we expect medicine to work: Smart. Targeted. Effective. Safe. Ignyta is on the leading edge of this research, offering hope where, for so long, there has been only fear.
At Ignyta, we work tirelessly on behalf of patients with cancer to offer potentially life-saving, precisely targeted therapeutics (Rx) guided by companion diagnostic (Dx) tests. Our integrated Rx/Dx strategy allows us to enter uncharted territory, illuminating the molecular drivers of cancer and quickly advancing treatments to address them. This approach embraces even those patients with the rarest cancers, who have the highest unmet need and who may otherwise not have access to effective treatment options. With our pipeline of potentially first-in-class and best-in-class precision medicines, we are pursuing the ultimate goal of not just shrinking tumors, but eradicating cancer relapse and recurrence in precisely defined patient populations.“